- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt
| EU orphan designation number: | EU/3/16/1757
|
| Active ingredient: | N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt |
| Indication: | Treatment of myelofibrosis |
| Sponsor: | Imago BioSciences Ltd.
Church Cottage, 28 Broadway, Chilton Polden,TA7 9DP, United Kingdom |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 18/10/2016 | Orphan designation | EMA/OD/115/16 | (2016)6749 of 14/10/2016 |
CONTACT
EU links
Directorate General Health & Consumers